北美消化不良药物市场，按类型（器质性消化不良、非溃疡性消化不良、药物引起的消化不良等）、治疗类型（药物和手术）、药物类型（品牌和通用）、处方（非处方药和处方药）、给药途径（口服和注射）、性别（男性和女性）、最终用户（医院、诊所、家庭护理机构、专科诊所、门诊手术中心、学术和政府研究机构等）、分销渠道（直接招标和零售销售）划分 - 行业趋势和预测到 2030 年。
北美Dyspepsia药物市场分析和透视
由于痢疾的流行和不健康的生活方式日益被采用,预计北美痢疾药物市场在预测期间会增长. 市场也受到了代谢失调症发病率上升的影响. 然而,北美的痢疾药物市场预计会受到用于痢疾药物可能产生的副作用和日益偏好自然和草药疗法的阻碍. 日益老龄化的人口和药物批准量的增加预计将成为市场增长的机会。 然而,严格的条例和民众对痢疾缺乏认识,预计将给市场增长带来挑战。
数据桥市场研究分析认为,在2023年到2030年的预测期间,北美的德斯珀斯药物市场预计将以5.6%的CAGR增长.
|
报表计量 |
细节 |
|
预测期 |
2023年至2030年统计 |
|
基准年 |
2022 |
|
历史年代 |
2021 (2015-2020年可定制). |
|
数量单位 |
单位单位收入和定价 |
|
覆盖部分 |
类型(组织性Dyspepsia、非Ulcer Dyspepsia、由药物诱导的Dyspepsia等)、治疗类型(医疗和外科)、药物类型(常规和普通)、处方(无处方药和处方药)、管理途径(口服和注射药)、性别(男用和女用)、最终用户(医院、诊所、家庭护理设施、特别诊所、门诊中心、学术和政府研究所等)、分销渠道(发货和零售销售) |
|
涵盖国家 |
美国、加拿大和墨西哥 |
|
覆盖的市场玩家 |
Bayer AG、Cadila制药公司、Sanofi、Lupin、Abbott、Perrigo Company plc、AstraZeneca、Procter和Gamble、以及Reckitt Benckiser等。 |
市场定义
消化道(Dyspepsia),通称消化道,是食后腹部所经历的疼痛和不适. 它通常是一种基本病症的征兆,如GERD(气管还原性疾病)、胆固醇和溃疡疾病等。 糖尿病的治疗取决于病因和严重程度。 治疗某种基本病症或改变一个人的药物会减少发作. Dyspepsia主要分为2个类别:"有机"和"功能性干燥"(FD). 造成痢疾的有机原因有:化脓溃疡、胃溃疡再生疾病、胃癌或食道癌、胰腺或双胞胎失调、对食物或药物的不容忍以及其他传染病或系统性疾病。 功能性失眠症(Dis-PEP-see-uh)是一个术语来指无明显原因的心烦的胃的反复症状. 功能性硬化症也叫非溃疡硬化症.
北美毒品市场动态
本节讨论了解市场驱动力、优势、机会、制约因素和挑战。 下文详细讨论所有这些问题:
驾驶员
- 日益流行的痢疾
消化道(Dyspepsia),通称消化道,是影响北美数百万人的一种胃肠道障碍. 此症能使上腹出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出入出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出 食用过快,食用辣或脂肪食品等多种因素,或作为药物的副作用,都可以引起多肽.
痢疾日益普遍,是导致痢疾药物市场增长的关键因素之一. 痢疾发病率上升可归因于生活方式、饮食习惯和人口老龄化等若干因素。 随着人老化,他们更容易被消化问题所感染,包括呼吸道衰竭. 随着老年人数的不断增长,对痢疾药物的需求也有所增加.
此外,不同的消化道疾病,如易发性肠道综合征,胃病,胃溃疡病和化脓性溃疡病等,也因上述疾病的发病率不断上升而引起痢疾. 因此,造成痢疾的痢疾和其他消化障碍的日益流行,可望成为市场增长的动力。 使用痢疾药物来缓解痢疾的症状并治疗痢疾,有潜力改善患者的结果并减轻痢疾的负担. 因此,痢疾的日益普遍正在推动全世界对痢疾药物的需求,从而增加痢疾在人口中的发病率和流行率。
- 采取不健康的生活方式
近年来,不健康的生活方式的采用率上升了,这助长了痢疾的流行. 健康不良的生活方式选择,如加工食品中高膳食,缺乏锻炼,酒精消费过量等,都可能造成痢疾.
因此,随着人们寻求缓解其症状,对痢疾药物的需求也相应增加. 德丙类药物市场通过各种药物,包括质子泵抑制剂,H2受体对抗剂和安打剂,来响应这种需要.
采取不健康的生活方式的上升可归因于若干因素,包括饮食习惯的改变、压力程度的提高和定居的生活方式。 现代生活的特点是工作时间长,压力大,容易获得快餐和其他不健康的选择。 这些因素可导致呼吸道失常和其他相关疾病,如胃溃疡再生病(GERD).
总之,痢疾是一种常见的病症,可能由各种因素所引起,包括不健康的生活方式选择. 采用不健康生活方式的兴起促使了白喉的流行,对有效白喉药物的需求也相应增加,预计将成为市场增长的动力.
机会
- 人口老龄化
根据估计,到2050年,65岁及以上的人口预计将达到15亿,这表明世界人口正在迅速老化并不断老化。 随着年龄的增长,人们患慢性病的风险更高。 这包括消化障碍等可因衰老而发作的呼吸道障碍.
人口不断增长和老化,为扩大痢疾毒品市场提供了重要机会。 由于越来越多的人对其消化系统有问题,因此越来越需要有效的治疗,可以降低症状的严重性并提高其整体生活质量.
此外,对痢疾的治疗可能需要专门针对老龄人口的需要。 老年人有可能患有多起慢性病并同时服用多起药物,两者都可能增加药物负相互作用和副作用的可能性. 因此,人们需要抗痢药物,这些药物对老年人既无风险又有效。 老年人还丧失了身体和免疫力,导致包括痢疾在内的多起与胃有关的疾病日益流行。
因此,老年人口的增加会引起痢疾及其症状,人们更喜欢预防性保健,这有望成为痢疾药物市场增长的机会。
重排/挑战
- 民众对痢疾缺乏认识
缺乏技能已经影响到国家,越来越多的人被迫等待6个多月的口腔治疗。 由于技术进步、基本基础设施和若干其他因素,新兴或发展中国家缺乏Dyspepsia Drug领域的熟练专业人员。
缺乏熟练的专业人员,部分原因是需要严格的教育和培训才能成为牙科专业人员以及竞争性的就业市场。 此外,技术熟练的牙医需要更多受过正规培训、有执照的牙医助理,帮助维持和增加口腔保健,以便操作和执行先进的技术系统,如痢疾药物系统。
新兴国家缺乏无法有效操作新技术的熟练专业人员。 这可能给市场带来出现新技术的挑战,因为这些国家正在拖延技术驱动的市场进步的开始。
最近的事态发展
- 2023年4月,萨诺菲宣布已经完成了对Provention Bio股份有限公司的收购. 这一收购帮助了公司扩展了通医业务.
- 2022年7月,ANI制药股份有限公司宣布从一家私人拥有的生化制药公司Oakrum Pharma(LLC)购买了4个缩写的新药应用(ANDAs).
北美毒品市场
北美的痢疾药物市场分为类型,治疗类型,药物类型,处方,管理路线,性别,最终用户,以及分销渠道. 不同部门之间的增长有助于你分析特殊的增长领域和接近市场的战略,并确定你的核心应用领域以及目标市场的差异。
类型
- 非紫外线
- 有机针叶虫
- 诱导的药物
- 其他人员
根据类型,北美的德丙分出药物市场分为有机德丙分出,非溃疡德丙分出,由药物诱发德丙分出等.
治疗类型
- 药品
- 外科手术
根据治疗类型,北美痢疾药物市场被分入了药物和外科.
药物类型
- 品牌
- 常规
基于药物类型,北美大便药物市场被分出为通用,并被打上品牌.
处方
- 无处方药
- 处方药
基于处方,北美的痢疾药物市场被分割成没有处方药和处方药.
行政路线
- 口头
- 可注射
根据管理路线,北美大便药物市场分为口服和注射.
性别
- 男性
- 妇女
以性别为基础,北美的痢疾药物市场分为男性和女性.
结束用户
- 医院
- 诊所
- 家庭护理设置
- 专科诊所
- 救护车中心
- 学术和政府研究所
- 其他人员
根据最终用户情况,北美的痢疾药物市场分为医院、诊所、家庭护理场所、专科诊所、流动外科中心、学术和政府研究机构等。
分发频道
- 直接招标
- 零售
根据发售渠道,北美大便药市场被分割成直接招标和零售.
北美Dyspepsia药物市场区域分析/观察
对北美的痢疾药物市场进行了分析,并根据类型、治疗类型、药物类型、处方、管理路线、性别、最终用户和分销渠道提供了市场规模的见解和趋势。
本市场报告涵盖的国家有美国、加拿大和墨西哥。
由于医疗开支上升和该国新陈代谢障碍的高发率,预计美国会主导北美的痢疾药物市场.
报告的国家部分还提供了影响市场的因素和影响市场当前和未来趋势的市场监管变化。 下游和上游价值链分析,技术趋势,波特五力分析等数据点,以及案例研究,是用来预测个别国家市场情景的一些指针. 此外,在对国家数据进行预测分析的同时,还考虑了北美品牌的存在和可得性及其由于来自当地和国内品牌的大规模或稀缺竞争而面临的挑战以及国内关税和贸易路线的影响。
竞争性景观和北美药材市场份额分析
北美大便药市场竞争环境提供了竞争对手的细节. 详细情况包括公司概况、公司财务、创收、市场潜力、研发投资、新市场举措、北美存在、生产地点和设施、生产能力、公司优缺点、产品推出、产品宽度和广度以及应用优势。 上述数据点仅涉及公司对市场的关注。
在市场上经营的一些主要市场参与者有:拜耳AG,卡迪拉制药公司.,萨诺菲,吕平.,阿博特.,佩里戈公司plc,AstraZeneca,Procter & Gamble,以及雷克基特·本克西泽等.
SKU-
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA DYSPEPSIA DRUG MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END-USER COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 假設
3 執行摘要
4 高級洞察
4.1 佩爾斯特分析
4.2 波特五力模型
5 流行病學
消化不良治療的 6 個問題
7 個行業洞察：
8 北美消化不良藥物市場及監管
9 市場概覽
9.1 驅動程式
9.1.1 消化不良盛行率不斷上升
9.1.2 不健康生活方式的興起
9.1.3 代謝紊亂盛行率上升
9.2 限制
9.2.1 治療消化不良的藥物可能產生的副作用
9.2.2 對天然和草藥療法的偏好日益增加
9.3 機遇
9.3.1 老年人口不斷成長
9.3.2 藥品核准數量上升
9.4 挑戰
9.4.1 民眾缺乏對消化不良的認識
9.4.2 嚴格的監管
10 北美消化不良藥物市場（按類型）
10.1 概述
10.2 非潰瘍性消化不良
10.3 器質性消化不良
10.4 藥物性消化不良
10.5 其他
11 北美消化不良藥物市場（依治療類型）
11.1 概述
11.2 藥物治療
11.2.1 藥物
11.2.1.1 抗酸劑
11.2.1.1.1 質子幫浦抑制劑（PPI）
11.2.1.1.1.1 奧美拉唑
11.2.1.1.1.2 蘭索拉唑
11.2.1.1.1.3 埃索美拉唑
11.2.1.1.1.4 其他
11.2.1.1.2 H2阻斷劑
11.2.1.1.2.1 西咪替丁
11.2.1.1.2.2 法莫替丁
11.2.1.1.2.3 尼札替丁
11.2.1.1.2.4 雷尼替丁
11.2.1.1.2.5 其他
11.2.1.2 胃促動力生殖細胞
11.2.1.2.1 檸檬酸莫沙必利
11.2.1.2.2 甲氧氯普胺
11.2.1.2.3 西沙必利
11.2.1.2.4 鹽酸伊托必利
11.2.1.2.5 多潘立酮
11.2.1.2.6 其他
11.2.1.3 抗生素
11.2.1.3.1 利福昔明
11.2.1.3.2 阿莫西林
11.2.1.3.3 克拉黴素
11.2.1.3.4 甲硝唑
11.2.1.3.5 左氧氟沙星
11.2.1.3.6 四環素
11.2.1.3.7 其他
11.2.1.4 其他
11.2.2 非藥物
11.2.2.1 益生菌
11.2.2.1.1 乳酸桿菌
11.2.2.1.2 雙歧桿菌
11.2.2.1.3 芽孢桿菌
11.2.2.1.4 鏈球菌
11.2.2.1.5 其他
11.2.2.2 益生元
11.3 手術
12 北美消化不良藥物市場（依藥物類型）
12.1 概述
12.2 通用
12.3 品牌
13 北美消化不良藥物市場（依處方）
13.1 概述
13.2 非處方藥
13.3 處方藥
14 北美消化不良藥物市場（依給藥途徑）
14.1 概述
14.2 口頭
14.2.1 片劑
14.2.2 膠囊
14.3 注射劑
15 北美消化不良藥物市場（依性別）
15.1 概述
15.2 女性
15.2.1 30-50年
15.2.2 超過50年
15.2.3 年齡小於30歲
15.3 男
15.3.1 30-50年
15.3.2 超過50年
15.3.3 年齡小於30歲
16 北美消化不良藥物市場（依最終使用者）
16.1 概述
16.2 醫院
16.2.1 類型
16.2.1.1 公共
16.2.1.2 私人
16.2.2 層級
16.2.2.1 第 3 層
16.2.2.2 第 2 層
16.2.2.3 終端間幹擾源 1
16.3 診所
16.4 家庭照護環境
16.5 專科診所
16.6 門診中心
16.7 學術與政府研究機構
16.8 其他
17 北美消化不良藥物市場，依通路
17.1 概述
17.2 零售額
17.2.1 REATIL藥房
17.2.2 醫院藥房
17.2.3 網路藥局
17.3 直接投標
18 北美消化不良藥物市場（按地區）
18.1 北美
18.1.1 美國
18.1.2 加拿大
18.1.3 墨西哥
19 北美消化不良藥物市場、公司格局
19.1 公司份額分析：北美
20 SWOT分析
21 北美消化不良藥物市場、公司概況
21.1 賽諾菲
21.1.1 公司概況
21.1.2 收入分析
21.1.3 公司股份分析
21.1.4 產品組合
21.1.5 最近的發展
21.2 魯邦
21.2.1 公司概況
21.2.2 收入分析
21.2.3 公司股份分析
21.2.4 產品組合
21.2.5 近期發展
21.3 人類製藥
21.3.1 公司概況
21.3.2 收入分析
21.3.3 公司股份分析
21.3.4 產品組合
21.3.5 最近的發展
21.4 阿斯利康
21.4.1 公司概況
21.4.2 收入分析
21.4.3 公司股份分析
21.4.4 產品組合
21.4.5 最近的發展
21.5 拜耳公司
21.5.1 公司概況
21.5.2 收入分析
21.5.3 公司股份分析
21.5.4 產品組合
21.5.5 最近的發展
21.6 雅培
21.6.1 公司概況
21.6.2 收入分析
21.6.3 產品組合
21.6.4 最近的發展
21.7 ANI 製藥公司
21.7.1 公司概況
21.7.2 收入分析
21.7.3 產品組合
21.7.4 最近的發展
21.8 奧賽康藥業股份有限公司
21.8.1 公司概況
21.8.2 收入分析
21.8.3 產品組合
21.8.4 最近的發展
21.9 ASTERISK LABORATORIES（I）PVT。有限公司
21.9.1 公司概況
21.9.2 產品組合
21.9.3 最近的發展
21.1 卡迪拉製藥
21.10.1 公司概況
21.10.2 收入分析
21.10.3 公司股份分析
21.10.4 產品組合
21.10.5 最近的發展
21.11 韓美製藥股份有限公司
21.11.1 公司概況
21.11.2 收入分析
21.11.3 產品組合
21.11.4 最近的發展
21.12 麥克尼爾消費藥品公司（強生服務公司的子公司）
21.12.1 公司概況
21.12.2 收入分析
21.12.3 產品組合
21.12.4 最近的發展
21.13 大塚製藥株式會社
21.13.1 公司概況
21.13.2 收入分析
21.13.3 產品組合
21.13.4 最近的發展
21.14 百利高公司
21.14.1 公司概況
21.14.2 收入分析
21.14.3 產品組合
21.14.4 最近的發展
21.15 尊貴消費者醫療保健公司
21.15.1 公司概況
21.15.2 收入分析
21.15.3 產品組合
21.15.4 最近的發展
21.16 寶潔
21.16.1 公司概況
21.16.2 收入分析
21.16.3 產品組合
21.16.4 最近的發展
21.17 利潔時。
21.17.1 公司概況
21.17.2 收入分析
21.17.3 產品組合
21.17.4 最近的發展
21.18 紅山生物製藥有限公司
21.18.1 公司概況
21.18.2 收入分析
21.18.3 產品組合
21.18.4 最近的發展
21.19 SALIX PHARMACEUTICALS 或其附屬公司（BAUSCH HEALTH COMPANIES INC. 的子公司）
21.19.1 公司概況
21.19.2 收入分析
21.19.3 產品組合
21.19.4 近期發展
21.2 武田製藥股份有限公司
21.20.1 公司概況
21.20.2 收入分析
21.20.3 產品組合
21.20.4 近期發展
21.21 伍德沃德製藥
21.21.1 公司概況
21.21.2 產品組合
21.21.3 最近的發展
21.22 ZERIA製藥有限公司
21.22.1 COMPANY SNAPSHOT
21.22.2 REVENUE ANALYSIS
21.22.3 PRODUCT PORTFOLIO
21.22.4 RECENT DEVELOPMENT
22 QUESTIONNAIRE
23 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 2 NORTH AMERICA NON-ULCER DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 3 NORTH AMERICA ORGANIC DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 4 NORTH AMERICA DRUG INDUCED DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 5 NORTH AMERICA OTHERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 6 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 7 NORTH AMERICA MEDICATION IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 8 NORTH AMERICA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 9 NORTH AMERICA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 10 NORTH AMERICA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 11 NORTH AMERICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 12 NORTH AMERICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 13 NORTH AMERICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 14 NORTH AMERICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 15 NORTH AMERICA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 16 NORTH AMERICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 17 NORTH AMERICA SURGERY IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 18 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 19 NORTH AMERICA GENERIC IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 20 NORTH AMERICA BRANDED IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 21 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 22 NORTH AMERICA WITHOUT PRESCRIPTION DRUGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 23 NORTH AMERICA PRESCRIPTION DRUGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 24 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 25 NORTH AMERICA ORAL IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 26 NORTH AMERICA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 27 NORTH AMERICA INJECTABLE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 28 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 29 NORTH AMERICA FEMALE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 30 NORTH AMERICA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 31 NORTH AMERICA MALE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 32 NORTH AMERICA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 33 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 34 NORTH AMERICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 35 NORTH AMERICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 36 NORTH AMERICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 37 NORTH AMERICA CLINICS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 38 NORTH AMERICA HOMECARE SETTINGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 39 NORTH AMERICA SPECIALTY CLINICS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 40 NORTH AMERICA AMBULATORY CENTERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 41 NORTH AMERICA ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 42 NORTH AMERICA OTHERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 43 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 44 NORTH AMERICA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 45 NORTH AMERICA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 46 NORTH AMERICA DIRECT TENDER IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 47 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 48 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 49 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 50 NORTH AMERICA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 51 NORTH AMERICA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 52 NORTH AMERICA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 53 NORTH AMERICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 54 NORTH AMERICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 55 NORTH AMERICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 56 NORTH AMERICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 57 NORTH AMERICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 58 NORTH AMERICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 59 NORTH AMERICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 60 NORTH AMERICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 61 NORTH AMERICA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 62 NORTH AMERICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 63 NORTH AMERICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 64 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 65 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 66 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 67 NORTH AMERICA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 68 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 69 NORTH AMERICA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 70 NORTH AMERICA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 71 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 72 NORTH AMERICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 73 NORTH AMERICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 74 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 75 NORTH AMERICA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 76 U.S. DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 77 U.S. DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 78 U.S. MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 79 U.S. DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 80 U.S. ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 81 U.S. PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 82 U.S. PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 83 U.S. PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 84 U.S. H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 85 U.S. H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 86 U.S. H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 87 U.S. GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 88 U.S. GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 89 U.S. GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 90 U.S. ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 91 U.S. ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 92 U.S. ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 93 U.S. NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 94 U.S. PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 95 U.S. PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 96 U.S. PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 97 U.S. DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 98 U.S. BRANDED IN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 99 U.S. DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 100 U.S. DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 101 U.S. ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 102 U.S. DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 103 U.S. FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 104 U.S. MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 105 U.S. DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 106 U.S. HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 107 U.S. HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 108 U.S. DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 109 U.S. RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 110 CANADA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 111 CANADA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 112 CANADA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 113 CANADA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 114 CANADA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 115 CANADA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 116 CANADA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 117 CANADA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 118 CANADA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 119 CANADA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 120 CANADA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 121 CANADA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 122 CANADA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 123 CANADA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 124 CANADA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 125 CANADA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 126 CANADA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 127 CANADA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 128 CANADA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 129 CANADA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 130 CANADA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 131 CANADA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 132 CANADA BRANDED IN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 133 CANADA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 134 CANADA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 135 CANADA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 136 CANADA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 137 CANADA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 138 CANADA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 139 CANADA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 140 CANADA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 141 CANADA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 142 CANADA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 143 CANADA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 144 MEXICO DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 145 MEXICO DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 146 MEXICO MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 147 MEXICO DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 148 MEXICO ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 149 MEXICO PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 150 MEXICO PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 151 MEXICO PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 152 MEXICO H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 153 MEXICO H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 154 MEXICO H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 155 MEXICO GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 156 MEXICO GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 157 MEXICO GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 158 MEXICO ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 159 MEXICO ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 160 MEXICO ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 161 MEXICO NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 162 MEXICO PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 163 MEXICO PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)
TABLE 164 MEXICO PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)
TABLE 165 MEXICO DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 166 MEXICO BRANDED IN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 167 MEXICO DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)
TABLE 168 MEXICO DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 169 MEXICO ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 170 MEXICO DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)
TABLE 171 MEXICO FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 172 MEXICO MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)
TABLE 173 MEXICO DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 174 MEXICO HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 175 MEXICO HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)
TABLE 176 MEXICO DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 177 MEXICO RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
图片列表
FIGURE 1 NORTH AMERICA DYSPEPSIA DRUG MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA DYSPEPSIA DRUG MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA DYSPEPSIA DRUG MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA DYSPEPSIA DRUG MARKET: NORTH AMERICA VS. REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA DYSPEPSIA DRUG MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA DYSPEPSIA DRUG MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA DYSPEPSIA DRUG MARKET: MULTIVARIATE MODELLING
FIGURE 8 NORTH AMERICA DYSPEPSIA DRUG MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA DYSPEPSIA DRUG MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA DYSPEPSIA DRUG MARKET: MARKET END-USER COVERAGE GRID
FIGURE 11 NORTH AMERICA DYSPEPSIA DRUG MARKET: SEGMENTATION
FIGURE 12 INCREASE IN THE PREVALENCE OF METABOLIC DISORDERS IS EXPECTED TO DRIVE THE NORTH AMERICA DYSPEPSIA DRUG MARKET GROWTH IN THE FORECAST PERIOD FROM 2023 TO 2030
FIGURE 13 NON-ULCER DYSPEPSIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA DYSPEPSIA DRUG MARKET IN 2023 & 2030
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA DYSPEPSIA DRUG MARKET
FIGURE 15 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TYPE, 2022
FIGURE 16 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TYPE, 2023-2030 (USD THOUSAND)
FIGURE 17 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 18 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TYPE, LIFELINE CURVE
FIGURE 19 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , 2022
FIGURE 20 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND)
FIGURE 21 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , CAGR (2023-2030)
FIGURE 22 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , LIFELINE CURVE
FIGURE 23 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY DRUG TYPE, 2022
FIGURE 24 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY DRUG TYPE, 2023-2030 (USD THOUSAND)
FIGURE 25 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 26 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 27 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, 2022
FIGURE 28 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, 2023-2030 (USD THOUSAND)
FIGURE 29 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, CAGR (2023-2030)
FIGURE 30 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, LIFELINE CURVE
FIGURE 31 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 32 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND)
FIGURE 33 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 34 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY GENDER, 2022
FIGURE 36 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY GENDER, 2023-2030 (USD THOUSAND)
FIGURE 37 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY GENDER, CAGR (2023-2030)
FIGURE 38 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY GENDER, LIFELINE CURVE
FIGURE 39 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY END USER, 2022
FIGURE 40 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 41 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY END USER, CAGR (2023-2030)
FIGURE 42 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 44 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 45 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 46 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 NORTH AMERICA DYSPEPSIA DRUG MARKET: SNAPSHOT (2022)
FIGURE 48 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY COUNTRY (2022)
FIGURE 49 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY COUNTRY (2023 & 2030)
FIGURE 50 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY COUNTRY (2022 & 2030)
FIGURE 51 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TYPE (2023-2030)
FIGURE 52 NORTH AMERICA DYSPEPSIA DRUG MARKET: COMPANY SHARE 2022 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
